We are advancing a pipeline of potent tumor-selective TCEs and targeted autoimmune therapeutics, aiming to increase therapeutic efficacy while minimizing side effects across both disease areas. Our candidates are designed with manufacturability in mind, featuring robust stability profiles and established production processes that enable efficient scale-up from research to clinical manufacturing.

CDR-Life’s unique M-gager® platform has the capability to target a broad spectrum of disease-specific antigens. In oncology, this includes challenging surface antigens as well as intracellular antigens displayed on the major histocompatibility complex (MHC). For autoimmune conditions, we precisely target disease-driving immune cell populations. Our modular format with unparalleled antigen binding specificity enables selective targeting of diseased cells while sparing healthy tissues. By combining precise targeting with a modular and flexible format, CDR-Life is developing truly selective therapeutics that can leverage immune responses based on disease context. Our unique M-gager® platform can deliver attractive clinical candidates in a matter of months, which provides an excellent basis for R&D collaborations on novel targets.

M-gager® demonstrates excellent drug properties

CDR-Life’s M-gager® platform is our proprietary technology designed to develop highly targeted, antibody-derived T cell engagers. Utilizing a unique phage display library with billions of small antibody fragments, we deliver a modular technology that achieves unparalleled antigen specificity in the T cell engager format, leading to effective and selective T cell recruitment. M-gager® molecules have excellent drug properties and are anticipated to be highly effective immunotherapies for a wide range of promising targets.

How do M-gager® molecules work?

The unique tumor antigen-specific moieties recognize and attach to cancer cells, while the anti-CD3 effector function engages CD3 on T cells. Concurrently, they signal a patient’s T cells to create a powerful cancer-fighting zone. The simultaneous binding of both the tumor antigen and CD3 promotes the formation of a cytolytic synapse between T cells and tumor cells, enabling T cells to release special proteins that can break down cancer cells without harming healthy ones.
As this process happens, the patient’s body creates more T cells specifically trained to recognize these cancer cells. Some of these new T cells become ‘memory cells,’ providing ongoing protection against cancer’s return. This immunological memory forms the basis for durable responses observed in some patients following successful immunotherapy. The activated T cells send out signals to attract even more immune cells to the tumor site. This triggers a coordinated, multi-pronged attack on cancer cells that can lead to more effective and longer-lasting treatment outcomes.

Collectively, M-gager^® molecules trigger a cascade of T cell biological effects including (1) T cell activation, (2) polyclonal expansion, (3) memory formation, and (4) peripheral recruitment, which together facilitate the synergistic lysis of tumor cells.